A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson’s disease model

References

• Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson’s disease. Curr Opin Neurol 2003;1:S3–S7.
   Google Scholar
• Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett 2010;469:159–163.
   PubMed Web of Science ®Google Scholar
• Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986;67:269–274.
   PubMed Web of Science ®Google Scholar
• Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 2010;5:e11838.
   PubMed Web of Science ®Google Scholar
• Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, Andersen JK. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 2007;27:13997–14006.
   PubMed Web of Science ®Google Scholar
• Woo SY, Kim JH, Moon MK, Han SH, Yeon SK, Choi JW, Jang BK, Song HJ, Kang YG, Kim JW, et al. Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. J Med Chem 2014;57:1473–1487.
   PubMed Web of Science ®Google Scholar
• Tarozzi A, Angeloni C, Malaguti M, Hrelia S, Hrelia P. Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid Med Cell Longev 2013;2013:415078.
   PubMed Web of Science ®Google Scholar
• Lee JA, Son HJ, Park KD, Han SH, Shin N, Kim JH, et al. A novel compound ITC-3 activates the Nrf2 signaling and provides neuroprotection in Parkinson's disease models. Neurotox Res 2015b;28:332–345.
   PubMed Web of Science ®Google Scholar
• Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 2011;14:2347–2360.
   PubMed Web of Science ®Google Scholar
• Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic Biol Med 2010;49:147–158.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168–175.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–397.
   PubMed Web of Science ®Google Scholar
• Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Cerebrospinal fluid inflammatory markers in Parkinson's disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183–189.
   PubMed Web of Science ®Google Scholar
• Castano A, Herrera AJ, Cano J, Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002;81:150–157.
   PubMed Web of Science ®Google Scholar
• Bassani TB, Vital MA, Rauh LK. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs. Arq Neuropsiquiatr 2015;73:616–623.
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim JH, Woo SY, Son HJ, Han SH, Jang BK, et al. A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model. Br J Pharmacol 2015;172:1087–1100.
   PubMed Web of Science ®Google Scholar
• Suri C, Fung BP, Tischler AS, Chikaraishi DM. Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J Neurosci 1993;13:1280–1291.
   PubMed Web of Science ®Google Scholar
• Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 1990;27:229–237.
   PubMed Web of Science ®Google Scholar
• Hwang O, Kim G, Jang YJ, Kim SW, Choi G, Choi HJ, et al. Synthetic phytoceramides induce apoptosis with higher potency than ceramides. Mol Pharmacol 2001;59:1249–1255.
   PubMed Web of Science ®Google Scholar
• Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ, et al. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 2009;16:361–371.
   PubMed Web of Science ®Google Scholar
• Son HJ, Lee JA, Shin N, Choi JH, Seo JW, Chi DY. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol 2012;165:2213–2227.
   PubMed Web of Science ®Google Scholar
• Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997. p 59–67.
   Google Scholar
• Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985;50:435–441.
   PubMedGoogle Scholar
• Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res 2010;1306:176–183.
   PubMed Web of Science ®Google Scholar
• Gao X, Talalay P. Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proc Natl Acad Sci USA 2004;101:10446–10451.
   PubMed Web of Science ®Google Scholar
• Han JM, Lee YJ, Lee SY, Kim EM, Moon Y, Kim HW, Hwang O. Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 2007;321:249–256.
   PubMed Web of Science ®Google Scholar
• Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005;224:171–184.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003;23:8137–8151.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Jang YJ, Kim HJ, Hwang O. Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol Pharmacol 2000;58:633–640.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Kim SW, Lee SY, et al. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 2003;86:143–152.
   PubMed Web of Science ®Google Scholar
• Lee SY, Moon Y, Choi DH, Choi HJ, Hwang O. Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: relevance to Parkinson's disease. Neurobiol Dis 2007;25:112–120.
   PubMed Web of Science ®Google Scholar
• Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011;198:221–231.
   PubMed Web of Science ®Google Scholar
• Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;22:11–17.
   PubMedGoogle Scholar
• Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205–214.
   PubMed Web of Science ®Google Scholar
• Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992;32:S128–S132.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176–183.
   PubMed Web of Science ®Google Scholar
• Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 2013;62:13–25.
   PubMed Web of Science ®Google Scholar
• Beyer RE, Segura-Aguilar J, Di Bernardo S, Cavazzoni M, Fato R, Fiorentini D, Galli MC, Setti M, Landi L, Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA 1996;93:2528–2532.
   PubMed Web of Science ®Google Scholar
• Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 1997;52:300–305.
   PubMed Web of Science ®Google Scholar
• Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004;65:1238–1247.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Chen TP, Wang YC, Lin YM, Lin PJ. HO-1 activation can attenuate cardiomyocytic apoptosis via inhibition of NF-kappaB and AP-1 translocation following cardiac global ischemia and reperfusion. J Surg Res 2009;155:147–156.
   PubMed Web of Science ®Google Scholar
• Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 2002;8:240–246.
   PubMed Web of Science ®Google Scholar
• Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000;6:422–428.
   PubMed Web of Science ®Google Scholar
• Kapturczak MH, Wasserfall C, Brusko T, Campbell-Thompson M, Ellis TM, Atkinson MA, Agarwal A. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 2004;165:1045–1053.
   PubMed Web of Science ®Google Scholar
• Syapin PJ. Regulation of haeme oxygenase-1 for treatment of neuroinflammation and brain disorders. Br J Pharmacol 2008;155:623–640.
   PubMed Web of Science ®Google Scholar
• Cuadrado A, Rojo AI. Heme oxygenase 1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 2008;14:429–442.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, Chen TY, Fahey JW, Talalay P. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013;329:163–177.
   PubMed Web of Science ®Google Scholar
• Xu C, Yuan X, Pan Z, Shen G, Kim JH, Yu S, Khor TO, Li W, Ma J, Kong AN. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther 2006;5:1918–1926.
   PubMed Web of Science ®Google Scholar
• Hu C, Eggler AL, Mesecar AD, van Breemen RB. Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol 2011;24:515–521.
   PubMed Web of Science ®Google Scholar
• Korenori Y, Tanigawa S, Kumamoto T, Qin S, Daikoku Y, Miyamori K, Nagai M, Hou DX. Modulation of Nrf2/Keap1 system by Wasabi 6-methylthiohexyl isothiocyanate in ARE-mediated NQO1 expression. Mol Nutr Food Res 2013;57:854–864.
   PubMed Web of Science ®Google Scholar
• Kumar H, Koppula S, Kim IS, More SV, Kim BW, Choi DK. Nuclear factor erythroid 2- related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death. CNS Neurol Disord Drug Targets 2012;11:1015–1029.
   PubMed Web of Science ®Google Scholar